D-0217-2025 Class II Terminated

Recalled by RemedyRepack Inc. — Indiana, PA

FDA drug recall D-0217-2025 was initiated by RemedyRepack Inc. on Jan 24, 2025 and is designated Class II. Reason for recall: CGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit. The recall status is terminated (terminated Jul 17, 2025). Affected quantity: 247 blister packs.

Recall details

Product Type
Drugs
Report Date
Feb 12, 2025
Initiation Date
Jan 24, 2025
Termination Date
Jul 17, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
247 blister packs

Product description

Carvedilol 25 mg Tablet, QTY: 30 Tablets per Blister Pack (3 x 10 blister cards), Rx Only, MFG by: Glenmark, Mahwah, NJ 07430, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC: 70518-3945-00.

Reason for recall

CGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit.

Distribution pattern

FL

Code information

Lot #s: J0777493050824, Exp. 5/31/2025; J0787856062124, Exp. 7/31/2025.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0217-2025
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0217-2025. Report a data issue: hello@regdatalab.com.